It is noteworthy that only one patient with KMT2A/MLL-R+ AML had FLT3-ITD whereas 47 patients from the KMT2A/MLL-R negative “other” group of pediatric AML patients were FLT3-ITD+, including patients with cytogenetically normal AML (N = 18); AML with inv[16] (N = 1); AML with t(15;17) (N = 12); AML with t(8;21) (N = 3); AML with other cytogenetic features (N = 9); and AML with unknown cytogenetic features (N = 4). Here, KMT2A is linked to acute myeloid leukemia.